|
Category: natural substances and extractives
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Assay: | 95.00 to 100.00 %
|
| Food Chemicals Codex Listed: | No |
| Boiling Point: | 441.90 °C. @ 760.00 mm Hg (est)
|
| Flash Point: | 430.00 °F. TCC ( 221.00 °C. ) (est)
|
| logP (o/w): | 3.790 (est) |
| Soluble in: |
| | water, 436.4 mg/L @ 25 °C (est) |
Organoleptic Properties:
| |
| Odor and/or flavor descriptions from others (if found). |
| |
| |
Cosmetic Information:
Suppliers:
Safety Information:
| Preferred SDS: View |
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
intraperitoneal-mouse LD50 265 mg/kg GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE Medicamentos de Actualidad. Vol. 14, Pg. 160, 1978.
intravenous-mouse LD50 28 mg/kg GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE Medicamentos de Actualidad. Vol. 14, Pg. 160, 1978.
oral-mouse LD50 3000 mg/kg United States Patent Document. Vol. #3852453
|
| Dermal Toxicity: |
|
Not determined
|
| Inhalation Toxicity: |
|
Not determined
|
Safety in Use Information:
| Category: | natural substances and extractives |
| Recommendation for (-)-eburnamonine usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for (-)-eburnamonine flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
References:
Other Information:
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| | eburnal | | | eburnal ritardo | | (3alpha,16alpha)- | eburnamenin-14(15H)-one | | (3-alpha,16-alpha)- | eburnamin-14(15h)-one | | | eburnamin-14(15H)-one, (3-alpha,16-alpha)- (9CI) | | (-)- | eburnamonina | | 3-alpha,16-alpha- | eburnamonine | | 3alpha,16alpha- | eburnamonine | | L- | eburnamonine | | | eburnamonine (-)-form | | | vinburnina | | | vinburnine | | | vinburnine [INN] | | | vinburninum | | | vincamona | | | vincamone |
Articles:
| PubMed: | Synthesis of 15-methylene-eburnamonine from (+)-vincamine, evaluation of anticancer activity, and investigation of mechanism of action by quantitative NMR. |
| PubMed: | Anti-cholinergic alkaloids as potential therapeutic agents for Alzheimer's disease: an in silico approach. |
| PubMed: | The synthesis of melohenine B and a related natural product. |
| PubMed: | Determination of the absolute configuration of 19-OH-(-)-eburnamonine using a combination of residual dipolar couplings, DFT chemical shift predictions, and chiroptics. |
| PubMed: | Exploiting the facile release of trifluoroacetate for the α-methylenation of the sterically hindered carbonyl groups on (+)-sclareolide and (-)-eburnamonine. |
| PubMed: | Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. |
| PubMed: | Reversal effects of Ca2+ antagonists on multidrug resistance via down-regulation of MDR1 mRNA. |
| PubMed: | Eburnamine derivatives and the brain. |
| PubMed: | Vinburnine decelerates [3H]N-methylscopolamine binding to recombinant human muscarinic M1-M4 acetylcholine receptors. |
| PubMed: | Asymmetric synthesis of (-)-eburnamonine and (+)-epi-eburnamonine from (4S)-4-ethyl-4-[2-(hydroxycarbonyl)ethyl]-2-butyrolactone. |
| PubMed: | A short synthesis of (+/-)-eburnamonine. |
| PubMed: | [Drug-induced enterocolitis. Important differential diagnosis in the investigation of diarrhea and intestinal hemorrhage]. |
| PubMed: | Red blood cell metabolism and hemoglobin oxygen affinity. Effect of vinburnine on normobaric hypoxic rats. |
| PubMed: | [Lymphocytic colitis likely attributable to use of vinburnine (Cervoxan)]. |
| PubMed: | Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. |
| PubMed: | Positive allosteric action of eburnamonine on cardiac muscarinic acetylcholine receptors. |
| PubMed: | Microbial hydroxylation of (-)-eburnamonine by Mucor circinelloides and Streptomyces violens. |
| PubMed: | Bullous fixed drug eruption induced by vinburnine. |
| PubMed: | [The effects of the acute administration of vinburnine on blood rheology, oxygen transport and regional circulation under normal conditions and in hypoxemia. In vivo research]. |
| PubMed: | [The effects of vinburnine on the blood rheology parameters and on the oxyhemoglobin dissociation curve and 2,3-diphosphoglycerate. In vitro research]. |
| PubMed: | Effects of vinburnine on experimental models of learning and memory impairments. |
| PubMed: | [The effect of modification of excipients for the bioavailability of vinburnine]. |
| PubMed: | Comparative evaluation of scavenger properties of exifone, piracetam and vinburnine. |
| PubMed: | [The oral liquid form of vinburnine: biopharmaceutics]. |
| PubMed: | Pharmacoclinical study of the action of vinburnin versus placebo: study of the hemodynamic, microcirculatory and rheological effects in angiopathy of the lower limbs in diabetes mellitus. |
| PubMed: | [Simultaneous determination of vinburnine and 6-hydroxyvinburnine in human plasma by high-performance liquid chromatography]. |
| PubMed: | Complexation behavior of vinburnine with beta and gamma cyclodextrins in aqueous solution and in the solid state. |
| PubMed: | Protective effects of vinpocetine and structurally related drugs on the lethal consequences of hypoxia in mice. |
| PubMed: | Occupational asthma caused by Voacanga africana seed dust. |
| PubMed: | A comparison of some of the pharmacological properties of the new eburnamenine derivative vindeburnol with those of vincamine, vinburnine, dihydroergotoxine mesilate and nicergoline. |
| PubMed: | Experimental clinical studies on the effect of eburnamonine in cerebrovascular disorders. |
| PubMed: | [Bioavailability of vinburnine in man: importance of combination with ascorbic acid]. |
| PubMed: | [A special flicker fusion frequency method for detection of the effects of gerontopharmaceuticals exemplified by the L-eburnamonine study]. |
| PubMed: | [Relative bioavailability of vinburnine in man (microgranules/gels)]. |
| PubMed: | Influence of aging and exogenous substances on cerebral energy metabolism in posthypoglycemic recovery. |
| PubMed: | Alkaloids from Roots of Strempeliopsis strempelioides - Structures of Strempeliopine and Strempeliopidine1. |
| PubMed: | Role of drugs in recovery of metabolic function of rat brain following severe hypoglycemia. |
| PubMed: | [Proton nuclear magnetic resonance in the pharmacologic study of cerebral edema]. |
| PubMed: | [Treatment of cerebrovascular deficiencies. Therapeutic evaluation from 129 cases using the double-blind method against placebo]. |
| PubMed: | Cerebral and cerebellar metabolic changes induced by drugs during the recovery period after profound hypoglycemia. |
| PubMed: | [Controlled multicenter clinical studies on the effect of (-)eburnamonine versus placebo in patients with chronic senile cerebral insufficiency of medium significance]. |
| PubMed: | 'Cerebroactive' drugs. Clinical pharmacology and therapeutic role in cerebrovascular disorders. |
| PubMed: | [Clinical and electrophysiologic changes produced by (--) eburnamonine in acute and post-acute stages of head injuries]. |
| PubMed: | Effects of acute and chronic treatment with (-)eburnamonine on the tissue supply of oxygen. |
| PubMed: | Influence of age upon the cerebral metabolic changes induced by acute hypoxia on the synaptosomes from dog brain. |
| PubMed: | [Clinical and experimental evaluation of the use of eburnamonine in acute anc chronic cerebro-vascular insufficiency]. |
| PubMed: | Experimental approach of activity and mechanism(s) of action of drugs used in cerebral metabolic insufficiency. Application to 1-eburnamonine. |
| PubMed: | Metabolic changes induced by acute hypoxia on the synaptosomes from dog brain. |
| PubMed: | [Electrophysiological variations induced by (-) eburnamonine in patients with chronic cerebrovascular insufficiency]. |
| PubMed: | [Clinical evaluation of (-) eburnamonine in chronic cerebrovascular insufficiency]. |
| PubMed: | [Open clinical trial with (-)eburnamonine in patients suffering from cerebral ischemia]. |
| PubMed: | Metabolism of vincamine in the rat in vivo and in vitro. |
| PubMed: | Age-dependent modification of drug interference on the enzymatic activities of the rat brain. |
| PubMed: | Cerebral metabolic and hemodynamic activities of l-eburnamonine in the anesthetized dog. A comparison with vincamine. |
| PubMed: | Drug action on cerebral energy state during and after various hypoxic conditions. |
| PubMed: | [Comparative study of 2 drugs used in the treatment of cerebral vascular insufficiency: I-Eburnamonine and Vincamine]. |
| PubMed: | Effect of (-)eburnamonine, papaverine and UDP-glucose on cerebral energy state during and after experimental hypoxia and ischaemia in beagle dog. |
| PubMed: | Retinal angiography in the study of cerebral ischemia. |
| PubMed: | CBF changes after (-)eburnamonine infusion in patients with cerebrovascular insufficiency. |
| PubMed: | (-)Eburnamonine in vascular lesions of the fundus of the eye (with 1 color plate). |
| PubMed: | Medical therapy of cerebral ischemia. Vasoactive and eumetabolic therapy. |
| PubMed: | Cerebral metabolic, hemodynamic and antihypoxic properties of l-eburnamonine. |
| PubMed: | Clinical evaluation of (-)eburnamonine in comparison with nicergoline in patients suffering from chronic brain ischemia. |
| PubMed: | Therapy of chronic consequences of brain ischemia. Comparison between two drugs acting on brain circulation and metabolism. |
| PubMed: | [Effect of L-eburnamonine on bronchial respiratory resistance in the anesthetized guinea pig. Comparison with vincamine]. |
| PubMed: | [Modifications by 1-eburnamonine and vincamine on 2,3-diphosphoglycerate blood levels in the presence or absence of histotoxic hypoxia produced by potassium cyanide in the awake rat]. |
| PubMed: | [Cerebral protecting activity of 1-eburnamonine studied on 3 models of acute hypoxic agression. Comparison with vincamine]. |
| PubMed: | [Study of the antihypoxic effect of eburnamonine in acute and recurrent anoxia on the cerebral electric activity in curarized rats. Comparison with vincamine]. |
| PubMed: | [To the pharmacology of the alkaloid eburnamonine]. |
| PubMed: | Absolute configuration of vincamine and some other alkaloids of the eburnamonine type. |
| PubMed: | GENERAL METHODS OF SYNTHESIS OF INDOLE ALKALOIDS. IV. A SYNTHESIS OF DL-EBURNAMONINE. |
|